RxDoctor Payments Data

Patrick Riedel, MD

Ophthalmology · Bloomington, MNNPI 1962497156

Payments from drug & device makers

$685in general payments, 2019–2025

Across 9 payments — averaging $76.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ocular Therapeutix, Inc.$156
  • AbbVie$156
  • Glaukos Corporation$143
  • Rxsight Inc$138
  • Alcon$76
  • Novartis$17

What the payments were for

  • Food & beverage$685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Ocular Therapeutix, Inc.1$156
AbbVie(2 entities)2$156
Glaukos Corporation2$143
Rxsight Inc2$138
Alcon1$76
Novartis1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$685 in reported general payments places this provider in the 60th percentile of 330 ophthalmology providers in Minnesota.

See all ophthalmology providers in Minnesota

Medicare billing

Part B allowed, 2024
$287,745
Medicare patients
591
Services billed
2,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost169$92,299
RestasisCyclosporine25$37,032
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol144$36,805
RhopressaNetarsudil Mesylate51$28,794
Latanoprost1,334$25,948
RocklatanNetarsudil Mesylat/Latanoprost40$25,504
Prednisolone Acetate697$23,631
Travoprost119$23,629
Brimonidine Tartrate424$22,863
VyzultaLatanoprostene Bunod32$12,754
Cyclosporine13$12,653
SimbrinzaBrinzolamide/Brimonidine Tart38$11,734
MoxifloxacinMoxifloxacin Hcl453$9,383
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat394$9,023
CombiganBrimonidine Tartrate/Timolol25$8,966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$156$144,530241 claims
AlconSimbrinza$76$11,73438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 330 ophthalmology providers in Minnesota.

Other ophthalmology in Bloomington

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →